July 9, 2020 / 11:19 AM / a month ago

BRIEF-Osmotica Pharmaceuticals Receives FDA Approval For Upneeq For Treatment Of Droopy Eyelid

July 9 (Reuters) - Osmotica Pharmaceuticals PLC:

* OSMOTICA PHARMACEUTICALS PLC RECEIVES FDA APPROVAL FOR UPNEEQ™ (OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION), 0.1% FOR ACQUIRED BLEPHAROPTOSIS (DROOPY EYELID) IN ADULTS

* OSMOTICA PHARMACEUTICALS PLC - REMAINS ACTIVELY ENGAGED IN DISCUSSIONS WITH EX-U.S. PARTNERS TO COMMERCIALIZE UPNEEQ IN MARKETS BEYOND U.S.

* OSMOTICA PHARMACEUTICALS PLC - PLANS TO MAKE UPNEEQ COMMERCIALLY AVAILABLE NEXT MONTH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below